The issuer is solely responsible for the content of this announcement. Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback